Fixed Monthly versus Less Frequent Ranibizumab Dosing and Predictors of Visual Response in Exudative Age-Related Macular Degeneration
Purpose. To examine temporal patterns of visual acuity (VA) response to pooled 0.3 mg/0.5 mg ranibizumab treatment in patients with age-related macular degeneration and identify potential baseline predictors of response. Design. Retrospective analysis. Methods. Results from 1824 ranibizumab-treated...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Journal of Ophthalmology |
| Online Access: | http://dx.doi.org/10.1155/2012/690641 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841524632107089920 |
|---|---|
| author | Seenu M. Hariprasad Lawrence S. Morse Howard Shapiro Pamela Wong Lisa Tuomi |
| author_facet | Seenu M. Hariprasad Lawrence S. Morse Howard Shapiro Pamela Wong Lisa Tuomi |
| author_sort | Seenu M. Hariprasad |
| collection | DOAJ |
| description | Purpose. To examine temporal patterns of visual acuity (VA) response to pooled 0.3 mg/0.5 mg ranibizumab treatment in patients with age-related macular degeneration and identify potential baseline predictors of response. Design. Retrospective analysis. Methods. Results from 1824 ranibizumab-treated patients receiving fixed monthly, quarterly, or as-needed dosing after three monthly loading doses in four phase III/IIIb trials (ANCHOR, MARINA, PIER, and SAILOR) were analyzed. Results. At month 3, 14.9% to 29.4% of patients had gained ≥15 letters. Not all patients achieved peak gains at month 3; many continued to have VA increases throughout treatment. After three monthly loading doses, continued monthly dosing resulted in further gains, as there were more delayed 15-letter responders at month 12 (14.7–16.1%) than with less frequent dosing (5.0–6.0%). Monthly dosing also resulted in more patients maintaining VA gains at later time points. Early 15-letter responders had lower baseline mean VA than delayed 15-letter responders in ANCHOR and MARINA; no other differences in baseline characteristics were noted. Conclusions. Although some patients have rapid improvements in VA, others do not experience peak VA until later during treatment. Continued monthly dosing resulted in a greater percentage of patients gaining ≥15 letters than with switching to less frequent dosing regimens. |
| format | Article |
| id | doaj-art-6fc408349d76425aa5d286bef156705f |
| institution | Kabale University |
| issn | 2090-004X 2090-0058 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Ophthalmology |
| spelling | doaj-art-6fc408349d76425aa5d286bef156705f2025-02-03T05:47:46ZengWileyJournal of Ophthalmology2090-004X2090-00582012-01-01201210.1155/2012/690641690641Fixed Monthly versus Less Frequent Ranibizumab Dosing and Predictors of Visual Response in Exudative Age-Related Macular DegenerationSeenu M. Hariprasad0Lawrence S. Morse1Howard Shapiro2Pamela Wong3Lisa Tuomi4Section of Ophthalmology and Visual Science, Department of Surgery, University of Chicago, 5841 S. Maryland Avenue, Chicago, IL 60637, USADepartment of Ophthalmology and Vision Science, University of California Davis Health System Eye Center, 4860 Y Street, Suite 2400 Sacramento, CA 95817, USAGenentech Inc., 1 DNA Way, South San Francisco, CA 94080, USAGenentech Inc., 1 DNA Way, South San Francisco, CA 94080, USAGenentech Inc., 1 DNA Way, South San Francisco, CA 94080, USAPurpose. To examine temporal patterns of visual acuity (VA) response to pooled 0.3 mg/0.5 mg ranibizumab treatment in patients with age-related macular degeneration and identify potential baseline predictors of response. Design. Retrospective analysis. Methods. Results from 1824 ranibizumab-treated patients receiving fixed monthly, quarterly, or as-needed dosing after three monthly loading doses in four phase III/IIIb trials (ANCHOR, MARINA, PIER, and SAILOR) were analyzed. Results. At month 3, 14.9% to 29.4% of patients had gained ≥15 letters. Not all patients achieved peak gains at month 3; many continued to have VA increases throughout treatment. After three monthly loading doses, continued monthly dosing resulted in further gains, as there were more delayed 15-letter responders at month 12 (14.7–16.1%) than with less frequent dosing (5.0–6.0%). Monthly dosing also resulted in more patients maintaining VA gains at later time points. Early 15-letter responders had lower baseline mean VA than delayed 15-letter responders in ANCHOR and MARINA; no other differences in baseline characteristics were noted. Conclusions. Although some patients have rapid improvements in VA, others do not experience peak VA until later during treatment. Continued monthly dosing resulted in a greater percentage of patients gaining ≥15 letters than with switching to less frequent dosing regimens.http://dx.doi.org/10.1155/2012/690641 |
| spellingShingle | Seenu M. Hariprasad Lawrence S. Morse Howard Shapiro Pamela Wong Lisa Tuomi Fixed Monthly versus Less Frequent Ranibizumab Dosing and Predictors of Visual Response in Exudative Age-Related Macular Degeneration Journal of Ophthalmology |
| title | Fixed Monthly versus Less Frequent Ranibizumab Dosing and Predictors of Visual Response in Exudative Age-Related Macular Degeneration |
| title_full | Fixed Monthly versus Less Frequent Ranibizumab Dosing and Predictors of Visual Response in Exudative Age-Related Macular Degeneration |
| title_fullStr | Fixed Monthly versus Less Frequent Ranibizumab Dosing and Predictors of Visual Response in Exudative Age-Related Macular Degeneration |
| title_full_unstemmed | Fixed Monthly versus Less Frequent Ranibizumab Dosing and Predictors of Visual Response in Exudative Age-Related Macular Degeneration |
| title_short | Fixed Monthly versus Less Frequent Ranibizumab Dosing and Predictors of Visual Response in Exudative Age-Related Macular Degeneration |
| title_sort | fixed monthly versus less frequent ranibizumab dosing and predictors of visual response in exudative age related macular degeneration |
| url | http://dx.doi.org/10.1155/2012/690641 |
| work_keys_str_mv | AT seenumhariprasad fixedmonthlyversuslessfrequentranibizumabdosingandpredictorsofvisualresponseinexudativeagerelatedmaculardegeneration AT lawrencesmorse fixedmonthlyversuslessfrequentranibizumabdosingandpredictorsofvisualresponseinexudativeagerelatedmaculardegeneration AT howardshapiro fixedmonthlyversuslessfrequentranibizumabdosingandpredictorsofvisualresponseinexudativeagerelatedmaculardegeneration AT pamelawong fixedmonthlyversuslessfrequentranibizumabdosingandpredictorsofvisualresponseinexudativeagerelatedmaculardegeneration AT lisatuomi fixedmonthlyversuslessfrequentranibizumabdosingandpredictorsofvisualresponseinexudativeagerelatedmaculardegeneration |